Hallervorden-Spatz disease: Historical case presentation in the spotlight of nosological evolution

Movement Disorders

Volumn 25, Issue 15, 2010, Pages 2486-2492

  Craenenbroeck, Amaryllis Van ^a   Gebruers, Marilien ^a   Martin, Jean Jacques ^a   Cras, Patrick ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Dystonia; Movement disorders; Pantothenate kinase 2

Indexed keywords

IRON; IRON CHELATING AGENT; PANTOTHENATE KINASE; PANTOTHENATE KINASE 2;

ACANTHOCYTOSIS; CACHEXIA; CEREBELLAR ATAXIA; CHOREA; CLINICAL EXAMINATION; COHORT ANALYSIS; DEMYELINATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EXTRAPYRAMIDAL SYMPTOM; FILM; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IRON CHELATION; KNOWLEDGE; MEDICAL ETHICS; MISSENSE MUTATION; MOTOR DYSFUNCTION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLIC FIGURE; REVIEW; SYMPTOM;

HISTORY, 20TH CENTURY; HUMANS; MOTION PICTURES AS TOPIC; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION;

EID: 78349296753     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23217     Document Type: Review

References (25)

1. Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus pallidus und der Substantia nigra. Z Gesammte Neurolog Psychiatr 1922; 79: 254-302.
2. Szanto J, Gallyas F. A study of iron metabolism in neuropsychiatric patients: Hallervorden-Spatz disease. Arch Neurol 1966; 14: 438-442.
3. Vincent C, Van Bogaert L. Contribution à l'étude des syndromes du globe pale. La dégénérescence progressive du globe pale et de la portion réticulée de la substance noire (Maladie d'Hallervorden-Spatz). Rev Neurol 1936; 65: 921-959.
4. Wigboldus JM, Bruyn GW. Hallervorden-Spatz-disease. In: Vinken JP, Bruyn GW, editors. Handbook of clinical neurology. Vol. 6: Diseases of the basal ganglia. Amsterdam: North Holland Publ. Co.; 1968. p 604-631.
5. Yanagisawa N, Shiraki H, Minakawa M, Narabayashi H. Clinico-pathological and histochemical studies of Hallervorden-Spatz disease with torsion dystonia with special references to diagnostic criteria of the disease from the clinico-pathological viewpoint. Prog Brain Res 1966; 21: 373-425.
6. Dreese MJ, Netsky MG. Degenerative disorders of the basal ganglia. In: Minckler J, Bailey OJ, Feigin I, Jervis G, Lindenberg R, Neubuerger KT, editors. Pathology of the nervous system, Vol. 1. New York: McGraw-Hill; 1968. p 1185-1204.
7. Seitelberger F. Pigmentary disorders. In: Minckler J, editor. Pathology of the nervous system, Vol. 2. New York: McGraw-Hill; 1971. p 1324-1338.
8. Perry TL, Norman MG, Yong VW, et al. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol 1985; 18: 482-489.
9. Eidelberg D, Sotrel A, Joachim C, et al. Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. Brain 1987; 110(Part 4): 993-1013.
10. Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988; 24: 692-694.
11. Higgins JJ, Patterson MC, Papadopoulos NM, Brady RO, Pentchev PG, Barton NW. Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology 1992; 42: 194-198.
12. Tripathi RC, Tripathi BJ, Bauserman SC, Park JK. Clinicopathologic correlation and pathogenesis of ocular and central nervous system manifestations in Hallervorden-Spatz syndrome. Acta Neuropathol 1992; 83: 113-119.
13. Taylor TD, Litt M, Kramer P, et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996; 14: 479-481.
14. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28: 345-349.
15. Ke Y, Ming Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003; 2: 246-253.
16. Hayflick SJ. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003; 15: 572-577.
17. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348: 33-40.
18. Baumeister FA, Auer DP, Hortnagel K, Freisinger P, Meitinger T. The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics 2005; 36: 221-222.
19. Seidelman W. Medicine and murder in the Third Reich. Available at: (accessed on November 27th, 2009).
20. Shevell M. Racial hygiene, active euthanasia, and Julius Hallervorden. Neurology 1992; 42: 2214-2219.
21. Shevell M. Hallervorden and history. N Engl J Med 2003; 348: 3-4.
22. Shevell MI, Peiffer J. Julius Hallervorden's wartime activities: implications for science under dictatorship. Pediatr Neurol 2001; 25: 162-165.
23. Baeck E. Ludo van Bogaert. Neurologist, bibliophile and patron of the arts. Brussels: UCB Pharma; 2003. 64 p+ ill.
24. Baeck E. Ludo van Bogaert (1897-1989) and the Bunge Institute. Eur J Neurol 2005; 12: 181-188.
25. Aubert G. Arthur van Gehuchten takes neurology to the movies. Neurology 2002; 59: 1612-1618.